NCT03961672 2026-01-05
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04331119 2025-12-30
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Washington University School of Medicine
Phase 2 Active not recruiting
NCT07293403 2025-12-19
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT05057247 2025-10-31
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05976997 2023-08-04
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Huazhong University of Science and Technology
Phase 2 Unknown
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT04209621 2022-03-09
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02605694 2021-03-17
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
SecuraBio
Phase 2 Withdrawn
NCT04707079 2021-01-13
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT02028039 2014-01-06
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn